EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Characterization of TSC1 and TSC2 Variants in a Greek Cohort of Tuberous Sclerosis Complex Patients

Socratis N Avgeris iD, Florentia Fostira iD, Paraskevi Apostolou iD, Angeliki Delimitsou iD, Stefanos Smyrniotis iD, Drakoulis Yannoukakos iD, Dimitrios J Stravopodis iD, Popi Syntichaki iD, Gerassimos E Voutsinas iD

Human Mutation · 2026-01 · 2026 (1)

DOI: 10.1155/humu/4508699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, online erschienen am 10.08.2026. Verfasst von Socratis N Avgeris und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Carcinogenesis and Rare Disease Genetics, Institute of Biosciences and Applications, National Centre for Scientific Research …. Hauptthemen laut MEDLINE: Tuberous Sclerosis, Tuberous Sclerosis Complex 2 Protein, Tuberous Sclerosis Complex 1 Protein, Tumor Suppressor Proteins. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem genetic disorder caused by pathogenic variants in the TSC1 or TSC2 genes, resulting in dysregulation of the mTOR signaling pathway and subsequent hamartoma formation. Although the genetic basis of TSC is well established, population‐specific data on TSC1 and TSC2 variants are still emerging. The aim of this study was to characterize the variant spectrum of the TSC1 and TSC2 genes in a cohort of 34 unrelated probands from Greece, 26 of whom had a definite TSC diagnosis, whereas eight had a possible TSC diagnosis. Targeted next‐generation sequencing (NGS) was performed to analyze all coding exons and flanking exon–intron boundaries of TSC1 and TSC2 . Identified variants were subsequently validated by Sanger sequencing. Pathogenic or likely pathogenic variants were identified in 22 of 34 probands, corresponding to an overall diagnostic yield of 65% using the testing strategy applied in this study. Of these variants, 32% (7/22) occurred in TSC1 and 68% (15/22) in TSC2 ; seven variants (7/22; 32%) were previously unreported. The molecular detection rate was 77% (20/26) for patients meeting the criteria for definite clinical TSC diagnosis and 25% (2/8) for those with a possible TSC diagnosis. Exploratory genotype–phenotype analysis revealed a trend toward a more severe clinical presentation among patients harboring TSC2 variants. These findings expand the known molecular landscape of TSC and support the clinical utility of genetic testing for diagnosis, genetic counseling, and patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberous SclerosisTuberous Sclerosis Complex 2 ProteinTuberous Sclerosis Complex 1 ProteinTumor Suppressor ProteinsHumansGreeceFemaleChildChild, PreschoolMaleInfantGenetic Association StudiesAdolescentHigh-Throughput Nucleotide SequencingCohort StudiesAdultMutationPhenotypeGenetic VariationYoung AdultExons

Substanzen

Tuberous Sclerosis Complex 2 ProteinTuberous Sclerosis Complex 1 ProteinTSC2 protein, humanTSC1 protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Laboratory of Molecular Carcinogenesis and Rare Disease Genetics, Institute of Biosciences and Applications, National Centre for Scientific Research (NCSR) "Demokritos", Athens, Greece.
  • Human Molecular Genetics Laboratory, INRASTES, National Centre for Scientific Research (NCSR) "Demokritos", Athens, Greece.
  • Section of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens (NKUA), Athens, Greece.
  • Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece.

ORCID-Profile: Socratis N Avgeris, Florentia Fostira, Paraskevi Apostolou, Angeliki Delimitsou, Stefanos Smyrniotis, Drakoulis Yannoukakos, Dimitrios J Stravopodis, Popi Syntichaki, Gerassimos E Voutsinas

Zitieren

APA

Avgeris, S. N., Fostira, F., Apostolou, P., Delimitsou, A., Smyrniotis, S., Yannoukakos, D., Stravopodis, D. J., Syntichaki, P., & Voutsinas, G. E. (2026). Molecular Characterization of TSC1 and TSC2 Variants in a Greek Cohort of Tuberous Sclerosis Complex Patients. Human Mutation, 2026(1). https://doi.org/10.1155/humu/4508699

Vancouver

Avgeris SN, Fostira F, Apostolou P, Delimitsou A, Smyrniotis S, Yannoukakos D, et al. Molecular Characterization of TSC1 and TSC2 Variants in a Greek Cohort of Tuberous Sclerosis Complex Patients. Human Mutation. 2026;2026(1). doi:10.1155/humu/4508699

BibTeX
@article{Avgeris2026,
  author = {Avgeris, Socratis N and Fostira, Florentia and Apostolou, Paraskevi and Delimitsou, Angeliki and Smyrniotis, Stefanos and Yannoukakos, Drakoulis and Stravopodis, Dimitrios J and Syntichaki, Popi and Voutsinas, Gerassimos E},
  title = {Molecular Characterization of TSC1 and TSC2 Variants in a Greek Cohort of Tuberous Sclerosis Complex Patients},
  journal = {Human Mutation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/humu/4508699}
}
Kostenlos starten →